FOLH1 and soft tissue sarcoma: The feasibility of a vascular disruption approach through PSMA-RLT for patients with soft tissue sarcoma is investigated in a Phase 1 clinical trial by the “Centre Hospitalier Universitaire Vaudois” (NCT05420727—ThernSarc).